NEWS April 17, 2017

BLOG: Cytovia, A Specialty Immuno-Oncology Pharmaceutical Company: From Vision Toward Implementation

Many IMNP shareholders have been asking about our vision and implementation plan for Cytovia. We now have a clear strategic business plan, validated by a leading consulting firm and by industry experts, to create a global specialty immuno-oncology pharmaceutical company around our core asset Ceplene.  As the plan is implemented, Cytovia would focus on commercialization […]

Keep Reading

March 27, 2017

What’s Next for Immune Pharma? Pure-Play Spin-Off Companies

Immune Pharma long term shareholders recognize the disconnect between the intrinsic value of each the key assets of the company and the stock price/ market valuation. The company first identified the potential to structure subsidiaries around asset groups: Immuno-Inflammation, Immuno-Oncology and Pain. After considering shared services from a parent company to the subsidiary, it appears that the […]

Keep Reading

EVENT March 11, 2017

Preliminary Data with Bertilimumab in an Open Label Phase 2a Study in the Rare Dermatological Auto-Immune Disease, Bullous Pemphigoid, presented at the American Academy of Dermatology 2017 Annual Meeting in Orlando, FL.

Preliminary Data with Bertilimumab in an Open Label Phase 2a Study in Bullous Pemphigoid were presented last Saturday at the American Academy of Dermatology 2017 Annual Meeting in Orlando, FL. Pr. Neil Korman, MD, PhD, FAAD spoke on March, 4th 2017 at the F076 – AUTOIMMUNE BLISTERING DISEASES: WHAT’S NEW scientific session, directed by Pr. […]

Keep Reading